Activated natural killer cell therapy - NantKwest

Drug Profile

Activated natural killer cell therapy - NantKwest

Alternative Names: aNK cells - NantKwest; CST-101; Neukoplast; NK-92 cells; ZRx-101

Latest Information Update: 08 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZelleRx
  • Developer Johann Wolfgang Goethe-Universitat Frankfurt am Main; NantCell; NantKwest; Rush University; University Health Network; University of Pittsburgh Medical Center; ZelleRx
  • Class Anti-infectives; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Pancreatic cancer
  • Preclinical Infections; Liver cancer
  • No development reported Acute myeloid leukaemia; Haematological malignancies; Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 27 Dec 2017 NantKwest initiates enrolment in the phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (Parenteral, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in Canada (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top